191 related articles for article (PubMed ID: 22054223)
1. Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE).
Jankovic J; Adler CH; Charles PD; Comella C; Stacy M; Schwartz M; Sutch SM; Brin MF; Papapetropoulos S
BMC Neurol; 2011 Nov; 11():140. PubMed ID: 22054223
[TBL] [Abstract][Full Text] [Related]
2. Primary results from the cervical dystonia patient registry for observation of onabotulinumtoxina efficacy (CD PROBE).
Jankovic J; Adler CH; Charles D; Comella C; Stacy M; Schwartz M; Manack Adams A; Brin MF
J Neurol Sci; 2015 Feb; 349(1-2):84-93. PubMed ID: 25595221
[TBL] [Abstract][Full Text] [Related]
3. Cervical dystonia and pain: characteristics and treatment patterns from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Charles PD; Adler CH; Stacy M; Comella C; Jankovic J; Manack Adams A; Schwartz M; Brin MF
J Neurol; 2014 Jul; 261(7):1309-19. PubMed ID: 24752807
[TBL] [Abstract][Full Text] [Related]
4. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
5. Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry.
Trosch RM; Espay AJ; Truong D; Gil R; Singer C; LeWitt PA; Lew MF; Tagliati M; Adler CH; Chen JJ; Marchese D; Comella CL
J Neurol Sci; 2017 May; 376():84-90. PubMed ID: 28431634
[TBL] [Abstract][Full Text] [Related]
6. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
Pagan FL; Harrison A
Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
[TBL] [Abstract][Full Text] [Related]
7. Neck Pain and Cervical Dystonia: Treatment Outcomes from CD PROBE (Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy).
Charles PD; Manack Adams A; Davis T; Bradley K; Schwartz M; Brin MF; Patel AT
Pain Pract; 2016 Nov; 16(8):1073-1082. PubMed ID: 26910788
[TBL] [Abstract][Full Text] [Related]
8. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.
Marsh WA; Monroe DM; Brin MF; Gallagher CJ
BMC Neurol; 2014 Apr; 14():91. PubMed ID: 24767576
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin type A therapy for cervical dystonia.
Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA Dosing, Disease Severity, and Treatment Benefit in Patients With Cervical Dystonia: A Cohort Analysis From CD PROBE.
Agarwal P; Barbano R; Moore H; Schwartz M; Zuzek A; Sadeghi M; Patel A
Front Neurol; 2022; 13():914486. PubMed ID: 35847221
[TBL] [Abstract][Full Text] [Related]
11. INTEREST IN CD2, a global patient-centred study of long-term cervical dystonia treatment with botulinum toxin.
Misra VP; Colosimo C; Charles D; Chung TM; Maisonobe P; Om S;
J Neurol; 2018 Feb; 265(2):402-409. PubMed ID: 29270685
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type B for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
[TBL] [Abstract][Full Text] [Related]
13. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
[TBL] [Abstract][Full Text] [Related]
14. Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.
Yun JY; Kim JW; Kim HT; Chung SJ; Kim JM; Cho JW; Lee JY; Lee HN; You S; Oh E; Jeong H; Kim YE; Kim HJ; Lee WY; Jeon BS
Mov Disord; 2015 Feb; 30(2):206-13. PubMed ID: 25476727
[TBL] [Abstract][Full Text] [Related]
15. Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia.
Chapman MA; Barron R; Tanis DC; Gill CE; Charles PD
Clin Ther; 2007 Jul; 29(7):1325-37. PubMed ID: 17825685
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox(®)) and incobotulinumtoxinA (Xeomin (®)).
Dressler D; Tacik P; Adib Saberi F
J Neural Transm (Vienna); 2014 Jan; 121(1):29-31. PubMed ID: 23913131
[TBL] [Abstract][Full Text] [Related]
17. A mixed treatment comparison to compare the efficacy and safety of botulinum toxin treatments for cervical dystonia.
Han Y; Stevens AL; Dashtipour K; Hauser RA; Mari Z
J Neurol; 2016 Apr; 263(4):772-80. PubMed ID: 26914922
[TBL] [Abstract][Full Text] [Related]
18. Minimal clinically important change in patients with cervical dystonia: Results from the CD PROBE study.
Dashtipour K; Mari Z; Jankovic J; Adler CH; Schwartz M; Brin MF
J Neurol Sci; 2019 Oct; 405():116413. PubMed ID: 31494402
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia.
Kazerooni R; Broadhead C
Am J Health Syst Pharm; 2015 Feb; 72(4):301-7. PubMed ID: 25631837
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A therapy for cervical dystonia.
Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
Cochrane Database Syst Rev; 2005 Jan; (1):CD003633. PubMed ID: 15674910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
